Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory Regulatory approval

FDA Agrees to Reduced 4WARD Trial Sample Size

Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA's agreement to reduce the sample size lowers the cost and time required for the 4WARD trial, potentially accelerating the path to regulatory submission and commercialization of mavorixafor for chronic neutropenia. This positive regulatory development is likely to boost investor confidence in X4 Pharmaceuticals, as reflected in the modest pre-market share price increase.

Biotechnology Pharmaceuticals

X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the United States — Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA agreed to reduce the trial's sample size from 176 to 126 participants, maintaining adequate statistical power for the co-primary endpoints of reduction in annualized infection rate and positive absolute neutrophil count response. The FDA also indicated that the proposed safety database would be acceptable to support a potential supplemental new drug application. X4 expects to complete enrollment by year-end 2026 and report topline data in the first half of 2028. The company's shares rose about 2% in pre-market trading following the announcement.

stock
X4 Pharmaceuticals is the sponsor of the 4WARD trial and the developer of mavorixafor. The FDA's agreement to reduce the sample size is a positive regulatory outcome that may reduce trial costs and accelerate development, supporting the company's stock.
Importance 100.0 Sentiment 30.0
govactor
The FDA is the regulatory authority that agreed to the reduced sample size and accepted the safety database for the potential sNDA. This decision is favorable for X4 but does not directly affect the FDA's own market sentiment.
Importance 90.0 Sentiment 0.0
per
Adam Craig is the Executive Chairman of X4 Pharmaceuticals and is quoted in the announcement. His role is to communicate the company's strategy and expectations, but he is not directly impacted by the event.
Importance 40.0 Sentiment 0.0
priv
Norgine is mentioned as a partner for commercialization of XOLREMDI in the European Union. The event does not directly affect Norgine, but a successful 4WARD trial could indirectly benefit its partnership with X4.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.